Teva Pharmaceutical Value Stock - Dividend - Research Selection
Market price: 10,79 USD
Teva Pharmaceutical Fundamental data and company key figures of the share
|Annual reports in USD|
|Net operating cash flow||748.000.000|
|Free cash flow||223.000.000|
|Liabilities & Shareholders equity||57.582.000.000|
|Diluted shares outstanding||1.090.610.000|
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Market Capitalization||11.767.682.048,00 USD|
|Raw Data Source||US GAAP in Millionen USD|
|Stock Split||2004-07-02,2.0000/1.0000; 2004-07-01,2.0000/1.0000; 2002-12-07,2.0000/1.0000; 2002-12-06,2.0000/1.0000; 2000-02-24,2.0000/1.0000; 2000-02-23,2.0000/1.0000; 2000-02-22,1.0000/1.0000; 1993-04-15,2.0000/1.0000; 1993-04-14,2.0000/1.0000; 1982-08-16,1.000000/1.000000|
Description of the company
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides specialty medicines for use in central nervous system and respiratory indications. Its products in the central nervous system area comprise Copaxone for the treatment of relapsing forms of MS; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. This segment\'s products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. The company has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.